Cyclacel Pharmaceuticals

OverviewSuggest Edit

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other serious diseases, particularly those of high unmet medical need, with a vision to improve patient healthcare with orally available innovative medicines. The Company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

TypePublic
Founded1992
HQBerkeley Heights, US
Websitecyclacel.com

Latest Updates

Employees (est.) (Mar 2019)14(+17%)
Revenue (FY, 2016)$843 K(-56%)
Share Price (Jun 2019)$0.6 (-1%)

Key People/Management at Cyclacel Pharmaceuticals

Spiro Rombotis

Spiro Rombotis

President and Chief Executive Officer
Paul McBarron

Paul McBarron

Executive Vice President, Finance and Chief Operating Officer and Secretary
David Glover

David Glover

Chief Scientist
Judy Chiao

Judy Chiao

Vice President, Clinical Development and Regulatory Affairs
Susan Davis

Susan Davis

Senior Director, Business Development and Project Management
Show more

Cyclacel Pharmaceuticals Office Locations

Cyclacel Pharmaceuticals has offices in Berkeley Heights and Dundee City
Berkeley Heights, US (HQ)
200 Connell Dr #1500
Dundee City, GB
1 James Lindsay Pl
Show all (2)

Cyclacel Pharmaceuticals Financials and Metrics

Cyclacel Pharmaceuticals Revenue

Cyclacel Pharmaceuticals's revenue was reported to be $843 k in FY, 2016 which is a 56.6% decrease from the previous period.
USD

Net income (Q2, 2019)

(1.8m)

EBIT (Q2, 2019)

(2.3m)

Market capitalization (10-Jun-2019)

9.5m

Closing stock price (10-Jun-2019)

0.6

Cash (30-Jun-2019)

15.2m
Cyclacel Pharmaceuticals's current market capitalization is $9.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.1m1.7m1.9m843.0k

Revenue growth, %

60%12%(57%)

General and administrative expense

7.8m5.7m5.5m5.3m5.4m

R&D expense

11.3m12.4m9.5m4.2m4.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

309.0k396.0k356.0k735.0k512.0k296.0k715.0k139.0k205.0k139.0k

General and administrative expense

1.5m1.5m1.4m1.4m1.5m1.3m1.2m1.4m1.3m1.3m1.4m1.3m1.2m1.4m1.3m1.3m1.2m1.2m

R&D expense

4.6m4.3m4.5m5.0m4.3m2.6m2.9m2.5m2.6m2.4m1.3m1.2m958.0k798.0k1.2m1.2m1.0m1.2m

Operating expense total

6.1m5.8m5.9m6.4m5.8m3.9m4.1m3.9m4.0m3.7m2.7m2.5m2.1m2.2m2.5m2.5m2.2m2.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

31.1m24.2m20.4m16.5m23.9m17.5m

Accounts Receivable

Inventories

3.4m4.6m4.1m

Current Assets

35.2m29.0m24.6m19.6m26.0m19.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

34.5m28.2m33.5m26.7m29.4m26.9m22.7m17.1m15.9m18.0m12.7m13.6m26.0m21.7m19.8m19.0m17.9m15.2m

Current Assets

37.7m33.5m37.3m31.2m35.0m30.5m26.8m21.3m18.8m22.6m17.0m16.1m27.8m24.7m22.7m20.7m20.1m18.2m

PP&E

285.0k305.0k454.0k45.0k33.0k29.0k

Total Assets

38.0m33.8m37.6m31.6m35.4m30.8m27.0m21.5m18.9m22.7m17.1m16.1m27.9m24.8m22.7m20.7m21.5m19.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.2m)(19.4m)(14.3m)(11.8m)(7.5m)(7.3m)

Depreciation and Amortization

70.0k174.0k210.0k133.0k32.0k29.0k

Inventories

Accounts Payable

(750.0k)666.0k(1.5m)370.0k(1.5m)554.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(6.6m)(4.9m)(9.7m)(14.6m)(4.9m)(8.3m)(11.0m)(3.0m)(6.0m)(9.0m)(1.6m)(3.7m)(5.6m)(1.3m)(3.2m)(5.3m)(1.8m)(3.6m)

Depreciation and Amortization

58.0k23.0k46.0k115.0k52.0k102.0k157.0k42.0k75.0k109.0k9.0k17.0k25.0k7.0k15.0k22.0k6.0k10.0k

Accounts Payable

837.0k1.2m313.0k(403.0k)887.0k(1.1m)(2.1m)(187.0k)316.0k464.0k(1.2m)(1.2m)(1.3m)(2.0k)(63.0k)8.0k(689.0k)(2.1m)

Cash From Operating Activities

(12.8m)(4.7m)(8.8m)(15.0m)(4.9m)(7.7m)(11.8m)(3.1m)(4.2m)(7.1m)(3.8m)(4.0m)(5.3m)(2.1m)(3.9m)(4.7m)(3.7m)(6.3m)
USDY, 2019

Financial Leverage

1.2 x
Show all financial metrics

Cyclacel Pharmaceuticals Online and Social Media Presence

Embed Graph

Cyclacel Pharmaceuticals News and Updates

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT –

Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

BERKELEY HEIGHTS, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biotech Showcase™…

Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

Conference Call Scheduled November 12, 2018 at 4:30 p.m. ET

Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Monday, Nov…

Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

BERKELEY HEIGHTS, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the 4th Annual Da…

Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

Multi-product agreement builds on long-term clinical collaboration in hematological malignancies Multi-product agreement builds on long-term clinical collaboration in hematological malignancies
Show more

Cyclacel Pharmaceuticals Blogs

Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results

Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results Content Import Tue, 08/13/2019 - 16:06 Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results 08/13/19 This release is a backfill from a News Wire Earnings …

Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results

Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results Content Import Wed, 08/07/2019 - 07:01 Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results 08/07/19 This release is a backfill from a News Wire Gene…

Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients Content Import Mon, 07/22/2019 - 07:01 Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine an…

Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019 Content Import Mon, 04/01/2019 - 07:08 Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AAC…

Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive biomarker of palbociclib efficacy -- BERKELEY HEIGHTS, N.J.

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

BERKELEY HEIGHTS, N.J. , March 20, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2018 financial
Show more

Cyclacel Pharmaceuticals Frequently Asked Questions

  • When was Cyclacel Pharmaceuticals founded?

    Cyclacel Pharmaceuticals was founded in 1992.

  • Who are Cyclacel Pharmaceuticals key executives?

    Cyclacel Pharmaceuticals's key executives are Spiro Rombotis, Paul McBarron and David Glover.

  • How many employees does Cyclacel Pharmaceuticals have?

    Cyclacel Pharmaceuticals has 14 employees.

  • Who are Cyclacel Pharmaceuticals competitors?

    Competitors of Cyclacel Pharmaceuticals include XOMA, AstraZeneca and Cantabio Pharmaceuticals.

  • Where is Cyclacel Pharmaceuticals headquarters?

    Cyclacel Pharmaceuticals headquarters is located at 200 Connell Dr #1500, Berkeley Heights.

  • Where are Cyclacel Pharmaceuticals offices?

    Cyclacel Pharmaceuticals has offices in Berkeley Heights and Dundee City.

  • How many offices does Cyclacel Pharmaceuticals have?

    Cyclacel Pharmaceuticals has 2 offices.